Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population

Cancer Genetics and Cytogenetics

Volumn 203, Issue 2, 2010, Pages 263-268

  Pandith, Arshad A ^a   Shah, Zafar A ^a   Khan, Nighat P ^a   Rasool, Roohi ^a   Afroze, Dil ^a   Yousuf, Adfar ^a   Wani, Saleem ^a   Siddiqi, Mushtaq ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; ADVANCED CANCER; ARTICLE; BLADDER CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE PREDISPOSITION; ETHNIC GROUP; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENETIC CORRELATION; GENOTYPE; GEOGRAPHIC ORIGIN; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARGININE; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDIA; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLINE; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 78650033605     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.08.010     Document Type: Article

References (43)

1. Ploeg M., Aben K.K.H., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol 2009, 27:289-293.
2. Ferlay J., Bray V., Isani P., Parkin D.M. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. ARC Cancer Base, no. 5 version 2.0 2004, IARC Press, Lyon.
3. Kamarana N.M., Kamat M.R., Kurkure A.P. National Cancer registry project. Indian Council of Medical Research 2000, (published in 2003).
4. Dhar G.M., Shah G.N., Naheed B., Hafiza Epidemiological trend in the distribution of cancer in Kashmir Valley. J Epidemiol Community Health 1993, 47:290-292.
5. Iacopetta B. TP53 Mutation in colorectal cancer. Human Mutation 2003, 21:271-276.
6. Whibley C., Pharoah P.D.P., Hollstein M. p53 polymorphisms: cancer implications. Nat Rev 2009, 9:95-107.
7. Soussi T., May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol 1996, 260:623-637.
8. Dalbagni G., Ren Z.P., Herr H., Cordon-Cardo C., Reuter V. Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study. Clin Cancer Res 2001, 7:2797-2801.
9. Prescott J.L., Montie J., Pugh T.W., McHugh T., Veltri R.W. Clinical sensitivity of p53 mutation detection in matched bladder tumour, bladder wash, and voided urine specimens. Cancer 2001, 91:2127-2135.
10. Chen W.C., Tsai F.J., Wu J.J., Wu H.C., Lu H.F., Li C.W. Distribution of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol Res 2002, 28:293-296.
11. Costa S., Pinto D., Pereira D., Rodrigues H., Camesselle-Teigeiro J., Medeiros R., Schmitt F. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 2008, 8:32.
12. Murphy M.E. Polymorphic variants in the p53 pathway. Cell Death & Differen 2006, 13:916-920.
13. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewshki G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999, 19:1092-1100.
14. Dumont P., Leu J.I., Della Pietra A., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365.
15. Leu J.I., Dumont P., Hafey M., Murphy M.E., Georges D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004, 6:443-450.
16. Marin M.C., Jost C.A., Brooks L.A., Irwin M.S., O'Nions J., Tidy J.A., et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000, 25:47-54.
17. Ignaszak-Szczepaniak M., Horst-Sikorska W., Sawicka J., Kaczmarek M., Slomski R. The TP53 codon 72 polymorphism and predisposition to adreno cortical cancer in Polish patients. Oncol Rep 2006, 16:65-71.
18. Toyama T., Zhang Z., Nishio M., Hamaguchi M., Kondo N., Iwase H., et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 2007, 9:34.
19. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., et al. Role of a p53 polymorphism in the development of human papilloma virus-associated cancer. Nature 1998, 393:229-234.
20. Helland A., Langerod A., Johnsen H., Olsen A.O., Skovlund E., Borresen-Dale A.L. p53 polymorphism and risk of cervical cancer. Nature 1998, 396:530-531.
21. Yu M.W., Yang S.Y., Chiu Y.H., Chiang Y.C., Liaw Y.F., Chen C.J. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 1999, 29:697-702.
22. Wang N.M., Tsai C.H., Yeh K.T., Chen S.J., Chang J.G. P53 codon 72 arg polymorphism is not a risk factor for carcinogenesis in the Chinese. Int J Mol Med 1999, 4:249-252.
23. Matlashewski G.J., Tuck S., Pim D., Lamb P., Schneider J., Crawford L.V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987, 7:961-963.
24. Pim D., Banks L. p53 polymorphic variants at codon 72 exerts different effects on cell cycle progression. Int J Cancer 2004, 108:196-199.
25. Wu X., Zhao H., Amos C.I., Sheets S., Nakan N., Hong W.K., et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002, 94:681-690.
26. Lung F.W., Lee T.M., Shu B.C., Chang F.H. P53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol 2004, 130:728-732.
27. Katkoori V.R., Jia X., Shanmugam C., Wan W., Meleth S., Bumpers H., et al. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 2009, 15:2406-2416.
28. Sourvinos G., Kazanis I., Delakas D., Cranidis A., Spandidos D.A. Genetic detection of bladder cancer by microsatellite analysis of p16, RB1 and p53 tumor suppressor genes. J. Urol 2001, 165:249-252.
29. Brooks L.A., Tidy J.A., Gusterson B., Hiller L., O'Nions J., Gasco M., et al. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papilloma virus. Cancer Res 2000, 60:6875-6877.
30. Jin X., Wu X., Roth J.A., Amos C.I., King T.M., Branch C., et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 1995, 16:2205-2208.
31. Soulitzis N., Sourvinos G., Dokianakas D., Spandidos D. P53 codon 72 polymorphism and its association with bladder cancer. Can Lett 2002, 179:175-183.
32. Kressner U., Inganas M., Byding S., Ingrid B., Lars P., Bengt G., et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999, 17:593-599.
33. Skaug V., Ryberg D., Kure E.H., et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000, 6:1031-1037.
34. Borresen A.L., Andersen T.I., Eyfjord J.E., Renee S.C., Steinunn T., Ake B., et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995, 14:71-75.
35. Erber R., Conradt C., Homann N., Christel E., Martin F., Andreas D., et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998, 16:1671-1679.
36. Adams C.H., Victor T.C., van Helden P.D. Polymorphisms and mutations found in the regions flanking exons 5 to 8 of theTP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genet Cytogenet 2003, 140:23-30.
37. Felley-Bosco E., Weston A., Cawley H.M., Bennett W.P., Harris C.C. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 1993, 53:752-759.
38. Omori S., Yoshida S., Kennedy S.H., Negoro K., Hamana S., Barlow D.H., Maruo T. Polymorphism at codon 72 of the p53 gene is not associated with endometriosis in a Japanese population. J Soc Gynecol Investig 2004, 11:232-236.
39. Sameer A.S., Shah Z.A., Syeed N., Banday M.Z., Bashir S.M., Bhat B.A., et al. TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genet Mol Res 2010, 9:651-660.
40. Beckman G., Birgander R., Sjalander A., Saha N., Holmgren P., Kivela A., Beckman L. Is p53 polymorphism maintained by natural selection?. Hum Hered 1994, 44:266-270.
41. Mani S., Rajaraman S., Ranganathan R., Veluswami S., Karunakaran N., Thanagrajan R. Role of GSTM1, GSTP1(II105Val) and p53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer-a case control study from South India. Asian Pacific J Cancer Prev 2007, 8:253-257.
42. Yao-Yuan H., Chich-Sheng L. P53 codon 11, 72 and 248 gene polymorphisms in endometriosis. Int J Biol Sci 2006, 2:188-193.
43. Sjalander A., Birgander R., Athlin L., Stenling R., Rutegard J., Beckman L., et al. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995, 16:1461-1464.